Status:
RECRUITING
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Lead Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Conditions:
Lymphoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or ref...
Eligibility Criteria
Inclusion
- Fully understand this study and voluntarily sign the ICF；
- Age ≥18 at ICF signing, regardless of gender；
- Histologically confirmed relapsed or refractory lymphoma.
Exclusion
- Lymphoma with known CNS involvement；
- Severe cardiovascular/cerebrovascular diseases.
- Any other reason deeming the participant unsuitable for the study, as judged by the investigator.
Key Trial Info
Start Date :
May 16 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06883526
Start Date
May 16 2025
End Date
May 1 2027
Last Update
January 5 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China